PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PAVmed (Nasdaq: PAVM), a commercial-stage medical technology company, has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 19, 2026 to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
The notification does not immediately affect PAVmed's listing status, and its shares will continue trading on the Nasdaq Capital Market under the symbol "PAVM". The company has stated its intention to take appropriate actions to cure the deficiency and regain compliance before the extended deadline.
PAVmed (Nasdaq: PAVM), un'azienda tecnologica medica in fase commerciale, ha ottenuto una proroga di 180 giorni da Nasdaq per ristabilire la conformità al requisito del prezzo minimo di offerta. L'azienda ha ora tempo fino al 19 gennaio 2026 per mantenere un prezzo di chiusura per azione di almeno 1,00 dollaro per un minimo di dieci giorni lavorativi consecutivi.
La notifica non influisce immediatamente sullo stato di quotazione di PAVmed, e le sue azioni continueranno a essere negoziate sul Nasdaq Capital Market con il simbolo "PAVM". L'azienda ha dichiarato l'intenzione di adottare le misure necessarie per correggere la situazione e tornare conforme entro la scadenza prorogata.
PAVmed (Nasdaq: PAVM), una empresa de tecnología médica en etapa comercial, ha recibido una extensión de 180 días por parte de Nasdaq para recuperar el cumplimiento con el requisito mínimo del precio de oferta. La compañía ahora tiene hasta el 19 de enero de 2026 para mantener un precio de cierre de al menos $1.00 por acción durante un mínimo de diez días hábiles consecutivos.
La notificación no afecta inmediatamente el estado de cotización de PAVmed, y sus acciones continuarán negociándose en el Nasdaq Capital Market bajo el símbolo "PAVM". La empresa ha declarado su intención de tomar las acciones adecuadas para corregir la deficiencia y recuperar el cumplimiento antes de la fecha límite extendida.
PAVmed (나스닥: PAVM)은 상업 단계의 의료 기술 회사로서, 최저 입찰가 요구 사항 준수를 회복하기 위해 나스닥으로부터 180일 연장을 받았습니다. 회사는 이제 2026년 1월 19일까지 최소 10영업일 연속으로 주당 최소 $1.00의 종가를 유지해야 합니다.
이번 통지는 PAVmed의 상장 상태에 즉각적인 영향을 미치지 않으며, 주식은 계속해서 나스닥 캐피털 마켓에서 "PAVM" 심볼로 거래됩니다. 회사는 연장된 기한 내에 결함을 수정하고 준수를 회복하기 위한 적절한 조치를 취할 계획임을 밝혔습니다.
PAVmed (Nasdaq : PAVM), une société de technologie médicale en phase commerciale, a obtenu une prolongation de 180 jours de la part du Nasdaq pour retrouver la conformité avec l'exigence de prix minimum d'offre. La société dispose désormais jusqu'au 19 janvier 2026 pour maintenir un cours de clôture d'au moins 1,00 $ par action pendant au moins dix jours ouvrables consécutifs.
Cette notification n'affecte pas immédiatement le statut de cotation de PAVmed, et ses actions continueront d'être négociées sur le Nasdaq Capital Market sous le symbole "PAVM". La société a déclaré son intention de prendre les mesures appropriées pour remédier à cette situation et retrouver la conformité avant la date limite prolongée.
PAVmed (Nasdaq: PAVM), ein Unternehmen der medizinischen Technologie im kommerziellen Stadium, hat von der Nasdaq eine 180-tägige Verlängerung erhalten, um die Einhaltung der Mindestgebotspreisanforderung wiederherzustellen. Das Unternehmen hat nun bis zum 19. Januar 2026 Zeit, einen Schlusskurs von mindestens 1,00 USD pro Aktie für mindestens zehn aufeinanderfolgende Handelstage zu halten.
Die Mitteilung wirkt sich nicht sofort auf den Notierungsstatus von PAVmed aus, und die Aktien werden weiterhin am Nasdaq Capital Market unter dem Symbol "PAVM" gehandelt. Das Unternehmen hat erklärt, dass es geeignete Maßnahmen ergreifen wird, um den Mangel zu beheben und die Einhaltung vor Ablauf der verlängerten Frist wiederherzustellen.
- Company granted additional 180 days to regain compliance
- Shares continue trading on Nasdaq without immediate delisting risk
- Stock price remains below $1.00 minimum bid requirement
- Risk of potential delisting if compliance is not achieved by January 2026
The notification has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol "PAVM."
To regain compliance with the Rule, the Company must maintain a closing bid price of at least
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-302517016.html
SOURCE PAVmed Inc.
FAQ
What is the deadline for PAVmed (PAVM) to regain Nasdaq compliance?
What happens to PAVmed (PAVM) stock trading status during the compliance period?
What must PAVmed (PAVM) do to regain Nasdaq compliance?
Why did Nasdaq grant PAVmed (PAVM) an extension for compliance?
